High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial
The intervention with high-dose amikacin in the 1st week of all-oral regimen was safe in this small cohort. A multi-country study is justified to investigate the efficacy to prevent acquired resistance.
Authors
- Tom Decroo (ORCID: https://orcid.org/0000-0002-1205-1484)
- J. Snobre (ORCID: https://orcid.org/0000-0001-7041-8216)
- François Hakizayezu
- Marieke G. G. Sturkenboom (ORCID: https://orcid.org/0000-0002-3420-0591)
- Leen Rigouts (ORCID: https://orcid.org/0000-0003-3301-9480)
- Natacha Herssens (ORCID: https://orcid.org/0000-0002-9231-3084)
- Claude Mambo Muvunyi (ORCID: https://orcid.org/0000-0003-4180-442X)
- Bouke C. de Jong (ORCID: https://orcid.org/0000-0002-1017-4675)
- Isabel Cuella Martin (ORCID: https://orcid.org/0000-0001-7543-3386)
- Patrick Migambi (ORCID: https://orcid.org/0000-0003-4344-2872)
- Bart K. M. Jacobs (ORCID: https://orcid.org/0000-0002-4677-0911)
- Corinne Merle (ORCID: https://orcid.org/0000-0003-4229-365X)
- Janvier Gasana (ORCID: https://orcid.org/0000-0003-3345-2065)
- Jean Claude Semuto Ngabonziza (ORCID: https://orcid.org/0000-0002-6075-5603)
- Yves Mucyo
- Jean Baptiste Ntihumbya
- Emeline de Viron
- Clement Ndayishimiye
- Docteur Runyambo
- A. Kilibazayire
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- World Health Organization (CH)
- Rwanda Biomedical Center (RW)
- Instituut voor Tropische Geneeskunde (BE)
Publication Details
- Journal
- IJTLD OPEN
- Published
- 2025-11-01
- DOI
- https://doi.org/10.5588/ijtldopen.25.0120
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.40